Gilead touts piv­otal da­ta for new kind of HIV ther­a­py, open­ing to­wards large po­ten­tial mar­ket

Pan­dem­ic aside, the last cou­ple years at Gilead have been all about ex­pan­sions: Mov­ing be­yond the HIV and he­pati­tis C an­tivi­rals that made them in­to a $77 bil­lion com­pa­ny and in­to the im­munol­o­gy and on­col­o­gy treat­ments that have be­come biotech’s bread and but­ter.

Still, key HIV projects have con­tin­ued as the Cal­i­for­nia biotech looks to stay on top of a field that still earns them north of $15 bil­lion per year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER